Aquestive Therapeutics (NASDAQ:AQST) Director Acquires 28,025 Shares of Stock

Aquestive Therapeutics, Inc. (NASDAQ:AQST) Director Richard Daly acquired 28,025 shares of the firm’s stock in a transaction on Tuesday, November 10th. The shares were bought at an average price of $3.54 per share, for a total transaction of $99,208.50. Following the completion of the transaction, the director owned 28,025 shares of the company’s stock, valued at approximately $99,208.50. This trade represents a ∞ increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website.

Aquestive Therapeutics Price Performance

Shares of Aquestive Therapeutics stock traded down $0.01 on Thursday, reaching $3.56. The company had a trading volume of 1,599,653 shares, compared to its average volume of 2,924,075. The firm has a market cap of $448.08 million, a price-to-earnings ratio of -5.57 and a beta of 1.49. The firm’s 50-day moving average price is $4.44 and its two-hundred day moving average price is $4.21. Aquestive Therapeutics, Inc. has a 1 year low of $2.93 and a 1 year high of $6.74.

Aquestive Therapeutics (NASDAQ:AQST) last released its earnings results on Tuesday, November 3rd. The company reported ($0.13) earnings per share for the quarter, missing the consensus estimate of ($0.12) by ($0.01). The firm had revenue of $7.56 million during the quarter, compared to analysts’ expectations of $11.02 million. As a group, analysts anticipate that Aquestive Therapeutics, Inc. will post -0.46 EPS for the current year.

Analyst Upgrades and Downgrades

A number of analysts recently weighed in on AQST shares. HC Wainwright reaffirmed a “buy” rating and issued a $10.00 price objective on shares of Aquestive Therapeutics in a research note on Friday, October 16th. Cantor Fitzgerald restated an “overweight” rating and issued a $11.00 price target on shares of Aquestive Therapeutics in a report on Thursday, September 10th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Aquestive Therapeutics in a research report on Thursday, October 15th. Finally, Wall Street Zen cut shares of Aquestive Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, November 7th. Three investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $8.75.

Institutional Inflows and Outflows

Several large investors have recently made changes to their positions in AQST. Blue Owl Capital Holdings LP bought a new stake in Aquestive Therapeutics during the second quarter valued at about $3,923,000. Latash Investments LLC purchased a new position in Aquestive Therapeutics in the second quarter valued at about $1,011,000. Wasatch Advisors LP raised its holdings in Aquestive Therapeutics by 57.8% in the second quarter. Wasatch Advisors LP now owns 1,385,843 shares of the company’s stock worth $5,765,000 after purchasing an additional 507,527 shares in the last quarter. BlackRock Inc. bought a new position in Aquestive Therapeutics in the second quarter worth about $33,569,000. Finally, Walleye Capital LLC bought a new position in Aquestive Therapeutics in the second quarter worth about $1,175,000. 32.45% of the stock is owned by institutional investors.

About Aquestive Therapeutics

Aquestive Therapeutics is a pharmaceutical company that develops medicines and drug-delivery technologies, with a focus on treatments for central nervous system disorders and severe allergic reactions. Its PharmFilm technology enables medicines to be delivered in dissolvable oral films. The company’s products and product portfolio have included Sympazan, a clobazam oral film for seizures associated with Lennox-Gastaut syndrome, and Libervant, a diazepam buccal film for seizure clusters. Aquestive has also developed film-based medicines with commercial partners, including formulations of Suboxone and Zuplenz.